Cymbalta Withdrawal Litigation Unsealed Documents
Declassified court documents obtained by Baum Hedlund during the course of the Cymbalta Withdrawal Litigation show that Eli Lilly and Company (the manufacturer of Cymbalta) was well aware of Cymbalta’s withdrawal risks, that they occur frequently and can be quite severe. Instead of being upfront about the risk, Lilly hid behind a misleading label, making it appear the risk was rare and symptoms mild.
Cymbalta Withdrawal Expert Trial Testimony and Exhibits
Expert Witness, Dr. Joseph Glenmullen, explains how Lilly obscured the risk of Cymbalta withdrawal.
Exhibit 001: Dr. Glenmullen Expert Witness Testimony
Exhibit 011: Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression
Exhibit 022: Highlights of Prescribing Information for Cymbalta
Exhibit 069: Duloxetine v. Venlafaxine Extended Release in Treatment of Major Depressive Disorder
Exhibit 070: Cymbalta: Supportive Optional Document to Duloxetine Core Data Sheet Pre-Read Based on Clinical Trial Data in Adult Population
Exhibit 078: Journal of Clinical Psychiatry Supplement – Antidepressant Discontinuation Syndrome: Update on SSRIs 1997
Exhibit 093: Journal Affective Disorders – Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder 2005
Exhibit 110: Table 4.138: Treatment-Emergent Adverse Events MedDRA
Exhibit 111: Table 4.35: Treatment-Emergent Adverse Events AMDP-5
Exhibit 112: Table 4.20: Treatment-Emergent-Adverse-Events-AMDP-5
Exhibit 119: Biological Psychiatry – SSRI Discontinuation Syndrome: A Randomized Clinical Trial 1998
Exhibit 151: Illustration Brain Cell Sending and Receiving SSRI Messages (1 of 2)
Exhibit 152: Illustration Brain Cell Sending and Receiving SSRI Messages (2 of 2)
Exhibit 661: Journal of Clinical Psychiatry – Prospective Studies of Adverse Events Related to Antidepressant Discontinuation 2006
Cymbalta Withdrawal Factual Summary and Exhibits
These court documents show Lilly’s knowledge of Cymbalta withdrawal.
Appendix A: Plaintiffs’ Proposed Facts – Hagan-Brown, Ali v. Eli Lilly
Exhibit 01: Deposition of Michael J. Detke
Exhibit 02: Walter Deberdt Email Re: Comments on SUI Clinical Expert Report
Exhibit 03: Journal Clinical Psychiatry – Antidepressant Discontinuation Syndrome: Update on SSRIs (1997)
Exhibit 04: SSRI Discontinuation Syndrome: A Randomized Clinical Trial (1998)
Exhibit 05: Ali v. Eli Lilly Defendant’s Responses to Plaintiff’s Amended First Set of Requests for Admission
Exhibit 06: Brintnall & Nicolini – Prozac Pyramid Positioning / Message Development Research
Exhibit 07: Eli Lilly U.S. Strategic Pricing Study – Cymbalta (2002)
Exhibit 08: Lilly Internal Email – Perahia, Detke, Wohlreich RE: Discontinuation Data
Exhibit 09: Deposition of Madelaine Wohlreich (4/29/2015)
Exhibit 10: Cymbalta Patient Segmentation Study (2004)
Exhibit 11: Saavedra v. Eli Lilly – Declaration of Sarah Helgeson (2013)
Exhibit 12: Study: Symptoms Following Abrupt Discontinuation of Duloxetine Treatment in Patients with Major Depressive Disorder (2005)
Exhibit 13: Ali v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents
Exhibit 14: Hagan-Brown v. Eli Lilly – Defendants’ Responses to Plaintiff’s First Set of Requests for Production of Documents
Exhibit 15: Letter – Covington to Baum Hedlund RE: Hagan-Brown, Ali v Eli Lilly (March 2015)
Exhibit 16: Cymbalta Annex I – Summary of Product Characteristics
Exhibit 17: Side by Side Comparison of U.S. and European Labels for Cymbalta
Exhibit 18: Deposition of Sharon Hoog
Exhibit 20: Deposition of Dr. Navera Ahmed
Exhibit 21: Deposition of Matt Kuntz
Exhibit 22: Lilly Internal Email – Williams, Detke RE: Withdrawal Scale for Duloxetine
Exhibit 23: Duloxetine vs. Venflaxine Extended Release in the Treatment of Major Depressive Disorder (2002-2003)
Exhibit 24: Deposition of Madelaine Wohlreich (4/30/2015)
Exhibit 25: Boehringer Ingelheim Clinical Trial Protocol Revision A (June 2004)
Exhibit 26: Lilly Clinical Report Form – Fluoxetine v. Sertraline and Paroxetine in Major Depression: Comparison of Discontinuation-Emergent Symptoms
Exhibit 27: Table 4.35 Treatment-Emergent Adverse Events Collected by AMDP-5
Exhibit 28: Table 4.20 Treatment-Emergent Adverse Events Collected by AMDP-5
Exhibit 29: Lilly Internal Email – Perahia, Spencer, Brannan RE: HMBU Taper Period (Oct. 2002)
Exhibit 30: Clinical Study Report: Duloxetine Hydrochloride 60mg or 120mg Once Daily Compared with Placebo in Patients with Generalized Anxiety Disorder
Exhibit 31: Lilly Internal Email – Wang, Bump, Sakai, Detke, Stephens RE: Follow-up on PLR Meeting
Exhibit 32: Deposition of Christine Phillips PhD
Exhibit 33: Memo From Division of Medication Errors and Technical Support (2007)
Exhibit 34: Letter from Dr. Glenmullen to Matthew Leckman (Sept. 2014)
Exhibit 35: Dr. Glenmullen Addendum to Cymbalta Withdrawal General Causation Report May 2015
Exhibit 36: Louis Morris PhD Expert Report Cymbalta Discontinuation Litigation
Exhibit 37: Louis Morris PhD Supplemental Expert Report Cymbalta Discontinuation Litigation
Exhibit 38: Deposition of Dr. Michael Clark
Exhibit 39: Guidance for Industry Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products – Content and Format
Exhibit 40: Lilly Internal Email – Lee, Perahia RE: Question on DEAE’s (Dec. 2010)
Exhibit 41: Lilly Internal Email – Ziering, Perahia RE: Duloxetine/Cymbalta Withdrawal Question (Oct. 2006)
Exhibit 44: Lilly Internal Email – Miles, Detke, Kajdasz, Desaiah RE: Resubmitted. Your Review Required Again for Disclosure Approval Request
Exhibit 45: Study: A Randomized, Double-Blind Comparison of Duloxetine and Venlafaxine in the Treatment of Patients with Major Depressive Disorder (2008)
Exhibit 46: Declaration of Dr. Joseph Glenmullen (Aug. 2013)
A ranking in The U.S. News – Best Lawyers® “Best Law Firms” is widely regarded by both client and legal professionals as a significant honor. It is considered the most reliable, unbiased source of legal referrals anywhere.
Wisner Baum is proud to be a sponsor of The Truck Safety Coalition, a a group of caring individuals dedicated to reducing the number of deaths and injuries caused by truck-related crashes. Our support enables them to help families and save lives.
Law360 recognizes law firms that have a strong regional presence, working on important matters within their home state. “[Wisner Baum] possesses a David v. Goliath-sized slingshot while seeking justice for everyday citizens it believes were harmed or killed through corporate wrongdoing.”
NLJ and American Lawyer Media honor law firms and attorneys as Elite Trial Lawyers for their cutting-edge legal work on behalf of plaintiffs in practice areas ranging from mass torts to securities litigation.
Best Lawyers is the oldest and most respected peer-review publication in the legal profession. A listing in Best Lawyers is widely regarded by both clients and legal professionals as a significant honor, conferred on a lawyer by his or her peers.
Less than one-half of one percent of firms across the nation have achieved this ranking. A firm must have a high percentage of lawyers who have achieved the prestigious AV® Preeminent rating by Martindale-Hubbell®.
The National Law Journal inducted Wisner Baum into the Verdicts Hall of Fame for obtaining the $2 billion landmark verdict in the Roundup cancer case of Pilliod et al. v. Monsanto. The verdict was #1 in California and #2 in the U.S. in 2019 and is #9 in American history.
Super Lawyers is a rating service of outstanding lawyers from more than 70 practice areas who have attained a high-degree of peer recognition and professional achievement.
The National Trial Lawyers Top 100 recognized the law firms of Wisner Baum, the Miller Firm and Audet & Partners with the 2019 Trial Team of the Year award (in the Mass Torts category) for their work in the groundbreaking case of Dewayne “Lee” Johnson v. Monsanto Company.
An AV® rating reflects an attorney who has reached the heights of professional excellence. The rating signifies the highest legal ability, and very high adherence to professional standards of conduct, ethics, reliability, and diligence.
Wisner Baum is proud to have all of its lawyers listed in Avvo, a legal directory connecting people in need of legal services with lawyers and connecting lawyers to lawyers. Eight of our attorneys have earned a 10.0 perfect rating with Avvo.
CA and USA
TopVerdict.com ranks our $2 billion verdict in Pilliod et al. v. Monsanto as the biggest verdict in California and the second largest verdict in the U.S. in 2019. It is the ninth largest verdict in U.S. history.
Published annually, the Lawdragon 500 Leading Plaintiff Consumer Lawyers list recognizes the “best of the best” in this area of the law through nominations, research, and review by a board of their peers.
In 2020, Law360 honored the law firms ”behind the litigation wins and major deals that resonated throughout the legal industry.” It recognized our success in several landmark cases.
In 2018, our $289 million Johnson v. Monsanto verdict was the largest personal injury verdict in California. TopVerdict.com also ranked it #2 among all verdicts in California and #10 in the nation.
The Bar Register is the definitive guide to the most distinguished law firms in America. It includes only those select law practices that have earned the highest rating in the Martindale-Hubbell Law Directory and have been designated by their colleagues as preeminent in their field.
Firm ReviewsWhat Our Clients Are Saying
I Can’t Imagine a Better Law Firm- Best Law Firms Survey
They Are About Changing the Systems...- Kim Witczak
Top Legal Minds in the Country- From Best Lawyers® Best Law Firms
Diligent & Professional Representation- W.T.
Our Best Interest Was Always Number One on Your List- G.C. & C.C